Cognizant reports Q3 adjusted EPS $1.25, consensus $1.15

Reports Q3 revenue $5.0B, consensus $5B. “Revenue growth in the third quarter was at the high end of our guidance range, driven by another quarter of strong performance in our largest segments, Health Sciences and Financial Services,” said CEO Ravi Kumar S. “Investments in AI-driven platforms, like our Neuro suite and Flowsource, are resonating with our clients and supporting our large deals success. In the third quarter, we signed six deals with total contract value of more than $100 million each, bringing our year-to-date count to nineteen, which is more than we signed in the full-year 2023. In August, we officially welcomed Belcan to the Cognizant (CTSH) family, and we are excited about the opportunities to jointly expand our presence in the growing ER&D market.”